The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
The swelling started with almost no warning, then seven-year-old Fiona Wardman’s hand ballooned like a rubber glove hooked to ...
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Astria Therapeutics (ATXS – Research Report), with ...
Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares acquire momentum first thing. The Cambridge, Mass.-based Intellia, a leading clinical-stage gene editing company focused on revolutionizing medicine ...
Lanadelumab has been found to be effective as long-term prophylaxis in reducing attack frequency in patients with HAE.
CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...
Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...
We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...
Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...